Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: Results from the multicentre TOcilizumab in Perioperative Period (TOPP) study

Modern Rheumatology

Volumn 23, Issue 3, 2013, Pages 440-449

  Momohara, Shigeki ^a   Hashimoto, Jun ^b   Tsuboi, Hideki ^b   Miyahara, Hisaaki ^c   Nakagawa, Natsuko ^d   Kaneko, Atsushi ^e   Kondo, Naoki ^f   Matsuno, Hiroaki ^g   Wada, Takahiko ^h   Nonaka, Tohgo ⁱ   Kanbe, Katsuaki ^a   Takagi, Haruki ^j   Murasawa, Akira ^k   Matsubara, Tsukasa ^l   Suguro, Toru ^m  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d Kohnan Kakogawa Hospital   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^f NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^g Matsuno Clinic for Rheumatic Diseases   (Japan)

^h KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

ⁱ KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j FUKUI PREFECTURAL HOSPITAL   (Japan)

^k Niigata Rheumatic Centre   (Japan)

^l Matsubara Mayflower Hospital   (Japan)

^m TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Orthopaedic surgery; Rheumatoid arthritis; Surgical site infection (SSI); Tocilizumab; Wound healing

Indexed keywords

C REACTIVE PROTEIN; TOCILIZUMAB;

ADULT; AGED; ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; HIP PROSTHESIS; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; OPERATION DURATION; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; PEROPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SURGICAL WOUND; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; WOUND HEALING IMPAIRMENT;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; PERIOPERATIVE PERIOD; SURGICAL WOUND INFECTION; WOUND HEALING;

EID: 84877751661     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0683-0     Document Type: Article

References (34)

1. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404-13.
2. Yano K, Ikari K, Inoue E, Tokita A, Sakuma Y, Hiroshima R, et al. Effect of total knee arthroplasty on disease activity in patients with established rheumatoid arthritis: 3-year follow-up results of combined medical therapy and surgical intervention. Mod Rheumatol. 2010;20(5):452-7.
3. Momohara S, Tanaka S, Nakamura H, Mibe J, Iwamoto T, Ikari K, et al. Recent trends in orthopedic surgery performed in Japan for rheumatoid arthritis. Mod Rheumatol. 2011;21(4):337-42.
4. Yasui T, Nishino J, Kadono Y, Matsui T, Nakamura K, Tanaka S, et al. Impact of biologics on the prevalence of orthopedic surgery in the National Database of Rheumatic Diseases in Japan. Mod Rheumatol. 2010;20(3):233-7.
5. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287-93.
6. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007;46(7):1157-60.
7. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(12):1713-20.
8. den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34(4):689-95.
9. Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol. 2010;29:495-500.
10. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int. 2004;25(5):331-5.
11. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(10):1810-4.
12. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55(2):333-7.
13. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007;25(3):430-6.
14. Suzuki M, Nishida K, Soen S, Oda H, Inoue H, Kaneko A, et al. Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. J Orthop Sci. 2011;16:778-84.
15. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68(10):1580-4.
16. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516-23.
17. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
18. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-97.
19. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-80.
20. Hirao M, Hashimoto J, Tsuboi H, Nampei A, Nakahara H, Yoshio N, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2009;68(5):654-7.
21. Hiroshima R, Kawakami K, Iwamoto T, Tokita A, Yano K, Sakuma Y, et al. Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab. Mod Rheumatol. 2011;21(1):109-11.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
23. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-8.
24. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19(4):351-7.
25. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20(4):250-278; quiz 279-280.
26. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford). 2010;49(2):341-7.
27. Momohara S, Kawakami K, Iwamoto T, Yano K, Sakuma Y, Hiroshima R, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21(5):469-75.
28. Nagamine R, Chen W, Hara T, Kondo K, Sugioka Y. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases. Mod Rheumatol. 2009;19(3):348-50.
29. Gallucci RM, Simeonova PP, Matheson JM, Kommineni C, Guriel JL, Sugawara T, et al. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J. 2000;14(15):2525-31.
30. Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol. 2003;73(6):713-21.
31. Luckett-Chastain LR, Gallucci RM. Interleukin (IL)-6 modulates transforming growth factor-beta expression in skin and dermal fibroblasts from IL-6-deficient mice. Br J Dermatol. 2009;161(2):237-48.
32. Wortel CH, van Deventer SJ, Aarden LA, Lygidakis NJ, Buller HR, Hoek FJ, et al. Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery. 1993;114(3):564-70.
33. Nishimoto N, Yoshizaki K, Tagoh H, Monden M, Kishimoto S, Hirano T, et al. Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol. 1989;50(3):399-401.
34. Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H, Monden M, et al. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery. 1992;111(2):201-9.